BioCentury | Apr 15, 2013
Clinical News

IGT preclinical data

...tumors treated with AVLB were 10 times smaller than the ones treated with Navelbine. IGT Pharma Inc. (VSE:IGT...
BioCentury | Jun 22, 2009
Clinical News

Generex Oral-lyn: Phase II data

...In a Phase II trial of 15 patients with impaired glucose tolerance (IGT), 12 puffs of...
BioCentury | Sep 25, 2006
Clinical News

Ramipril: Phase III data

...However, ramipril led to significant normalization of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT...
BioCentury | Mar 24, 2003
Company News

Metabolex, Yamanouchi deal

...2002 deal to develop therapeutics to treat Type II diabetes, insulin resistance, impaired glucose tolerance (IGT...
BioCentury | Mar 25, 2002
Company News

Metabolex, Yamanouchi deal

...Yamanouchi partnered to develop therapeutics to treat Type II diabetes, insulin resistance, impaired glucose tolerance (IGT...
BioCentury | Mar 20, 2002
Company News

Metabolex, Yamanouchi diabetes, obesity deal

...Japan) partnered to develop therapeutics to treat Type II diabetes, insulin resistance, impaired glucose tolerance (IGT...
BioCentury | Sep 17, 2001
Clinical News

Starlix nateglinide (A-4166): Began Phase III trial

...development of Type II diabetes and cardiovascular disease in people who have impaired glucose tolerance (IGT). WIR...
BioCentury | Aug 20, 2001
Strategy

On the horizon

...On the horizon Compound Indication Market Vardenafil Erectile dysfunction 2H2002 Acarbose Diabetes 2003/2004 IGT repinotan Stroke...
BioCentury | Jan 29, 2001
Strategy

Bayer's pipeline

...Cancer Phase II Implitapide Hyperlipidemia PDE4 inhibitor Asthma PDE4 inhibitor COPD Phase III Acarbose Diabetes IGT...
BioCentury | Oct 30, 2000
Company News

IGT, NTB Neurotrophic Bioscience Inc. deal

...NTB and IGT signed a letter of intent to merge. Under the deal, IGT will acquire...
...be chosen. The deal will combine both companies' expertise in neurologic disorders and neurotrophic factors. IGT Pharma Inc....
Items per page:
1 - 10 of 24
BioCentury | Apr 15, 2013
Clinical News

IGT preclinical data

...tumors treated with AVLB were 10 times smaller than the ones treated with Navelbine. IGT Pharma Inc. (VSE:IGT...
BioCentury | Jun 22, 2009
Clinical News

Generex Oral-lyn: Phase II data

...In a Phase II trial of 15 patients with impaired glucose tolerance (IGT), 12 puffs of...
BioCentury | Sep 25, 2006
Clinical News

Ramipril: Phase III data

...However, ramipril led to significant normalization of impaired fasting glucose (IFG) and impaired glucose tolerance (IGT...
BioCentury | Mar 24, 2003
Company News

Metabolex, Yamanouchi deal

...2002 deal to develop therapeutics to treat Type II diabetes, insulin resistance, impaired glucose tolerance (IGT...
BioCentury | Mar 25, 2002
Company News

Metabolex, Yamanouchi deal

...Yamanouchi partnered to develop therapeutics to treat Type II diabetes, insulin resistance, impaired glucose tolerance (IGT...
BioCentury | Mar 20, 2002
Company News

Metabolex, Yamanouchi diabetes, obesity deal

...Japan) partnered to develop therapeutics to treat Type II diabetes, insulin resistance, impaired glucose tolerance (IGT...
BioCentury | Sep 17, 2001
Clinical News

Starlix nateglinide (A-4166): Began Phase III trial

...development of Type II diabetes and cardiovascular disease in people who have impaired glucose tolerance (IGT). WIR...
BioCentury | Aug 20, 2001
Strategy

On the horizon

...On the horizon Compound Indication Market Vardenafil Erectile dysfunction 2H2002 Acarbose Diabetes 2003/2004 IGT repinotan Stroke...
BioCentury | Jan 29, 2001
Strategy

Bayer's pipeline

...Cancer Phase II Implitapide Hyperlipidemia PDE4 inhibitor Asthma PDE4 inhibitor COPD Phase III Acarbose Diabetes IGT...
BioCentury | Oct 30, 2000
Company News

IGT, NTB Neurotrophic Bioscience Inc. deal

...NTB and IGT signed a letter of intent to merge. Under the deal, IGT will acquire...
...be chosen. The deal will combine both companies' expertise in neurologic disorders and neurotrophic factors. IGT Pharma Inc....
Items per page:
1 - 10 of 24